社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
LIHUI
IP属地：未知
+关注
帖子 · 18
帖子 · 18
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
LIHUI
LIHUI
·
2021-07-12
.
Oil Slips on Growing Threat of Delta Variant to Demand<blockquote>德尔塔变异毒株对需求的威胁越来越大，油价下滑</blockquote>
(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurg
Oil Slips on Growing Threat of Delta Variant to Demand<blockquote>德尔塔变异毒株对需求的威胁越来越大，油价下滑</blockquote>
看
1,743
回复
评论
点赞
2
编组 21备份 2
分享
举报
LIHUI
LIHUI
·
2021-07-12
.
Oil Slips on Growing Threat of Delta Variant to Demand<blockquote>德尔塔变异毒株对需求的威胁越来越大，油价下滑</blockquote>
(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurg
Oil Slips on Growing Threat of Delta Variant to Demand<blockquote>德尔塔变异毒株对需求的威胁越来越大，油价下滑</blockquote>
看
2,178
回复
评论
点赞
3
编组 21备份 2
分享
举报
LIHUI
LIHUI
·
2021-06-08
Like please
Controversial Biogen Alzheimer Drug Wins FDA Approval<blockquote>备受争议的百健阿尔茨海默病药物获得 FDA 批准</blockquote>
In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's
Controversial Biogen Alzheimer Drug Wins FDA Approval<blockquote>备受争议的百健阿尔茨海默病药物获得 FDA 批准</blockquote>
看
3,328
回复
1
点赞
1
编组 21备份 2
分享
举报
LIHUI
LIHUI
·
2021-06-04
.
非常抱歉，此主贴已删除
看
2,769
回复
1
点赞
4
编组 21备份 2
分享
举报
LIHUI
LIHUI
·
2021-06-03
.
非常抱歉，此主贴已删除
看
3,478
回复
评论
点赞
1
编组 21备份 2
分享
举报
LIHUI
LIHUI
·
2021-06-02
.
AMC Stock Is Surging Again. How to Make Sense of the Move.<blockquote>AMC 股价再次飙升。如何理解这一举动？</blockquote>
AMC Entertainment‘s skyrocketing stock price would be easy to dismiss as just meme-trade madness, th
AMC Stock Is Surging Again. How to Make Sense of the Move.<blockquote>AMC 股价再次飙升。如何理解这一举动？</blockquote>
看
3,501
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
LIHUI
LIHUI
·
2021-06-01
.
非常抱歉，此主贴已删除
看
2,574
回复
1
点赞
2
编组 21备份 2
分享
举报
LIHUI
LIHUI
·
2021-06-01
Weeee
Zoom Video to Report Q1 Earnings: What's in the Cards?<blockquote>Zoom Video将公布第一季度收益：前景如何？</blockquote>
Zoom Video Communications is set to report first-quarter fiscal 2022 results on Jun 1.For the quarte
Zoom Video to Report Q1 Earnings: What's in the Cards?<blockquote>Zoom Video将公布第一季度收益：前景如何？</blockquote>
看
3,586
回复
1
点赞
点赞
编组 21备份 2
分享
举报
LIHUI
LIHUI
·
2021-05-28
.
非常抱歉，此主贴已删除
看
4,080
回复
4
点赞
1
编组 21备份 2
分享
举报
LIHUI
LIHUI
·
2021-05-27
.guu ya n
看
3,454
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3579418112520180","uuid":"3579418112520180","gmtCreate":1616324571094,"gmtModify":1620830636840,"name":"LIHUI","pinyin":"lihui","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":53,"tweetSize":18,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.33%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":142067113,"gmtCreate":1626104891732,"gmtModify":1631889244205,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"title":"","htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/142067113","repostId":"1143990601","repostType":4,"repost":{"id":"1143990601","kind":"news","pubTimestamp":1626102184,"share":"https://www.laohunote.com/m/news/1143990601?lang=zh_CN&edition=full","pubTime":"2021-07-12 23:03","market":"fut","language":"en","title":"Oil Slips on Growing Threat of Delta Variant to Demand<blockquote>德尔塔变异毒株对需求的威胁越来越大，油价下滑</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1143990601","media":"Bloomberg","summary":"(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurg","content":"<p><div> (Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China. Futures in New York fell as much as ...</p><p><blockquote><div>（彭博社）——由于交易员努力应对 Covid-19 在多个地区卷土重来和中国经济增长放缓带来的需求影响，油价小幅走低。纽约期货跌幅高达……</div></blockquote></p><p> <a href=\"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html\">网页链接</a> </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html\">网页连接</a></blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oil Slips on Growing Threat of Delta Variant to Demand<blockquote>德尔塔变异毒株对需求的威胁越来越大，油价下滑</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOil Slips on Growing Threat of Delta Variant to Demand<blockquote>德尔塔变异毒株对需求的威胁越来越大，油价下滑</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-07-12 23:03</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> (Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China. Futures in New York fell as much as ...</p><p><blockquote><div>（彭博社）——由于交易员努力应对 Covid-19 在多个地区卷土重来和中国经济增长放缓带来的需求影响，油价小幅走低。纽约期货跌幅高达……</div></blockquote></p><p> <a href=\"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html\">网页链接</a> </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143990601","content_text":"(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.\nFutures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.\n“As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.\nFuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.\nChina’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.\n“There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.\nThe delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.\nUncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.\n“They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.\nThe International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.","news_type":1,"symbols_score_info":{"CLmain":0.9}},"isVote":1,"tweetType":1,"viewCount":1743,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":142064787,"gmtCreate":1626104877449,"gmtModify":1631889244216,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"title":"","htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/142064787","repostId":"1143990601","repostType":4,"repost":{"id":"1143990601","kind":"news","pubTimestamp":1626102184,"share":"https://www.laohunote.com/m/news/1143990601?lang=zh_CN&edition=full","pubTime":"2021-07-12 23:03","market":"fut","language":"en","title":"Oil Slips on Growing Threat of Delta Variant to Demand<blockquote>德尔塔变异毒株对需求的威胁越来越大，油价下滑</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1143990601","media":"Bloomberg","summary":"(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurg","content":"<p><div> (Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China. Futures in New York fell as much as ...</p><p><blockquote><div>（彭博社）——由于交易员努力应对 Covid-19 在多个地区卷土重来和中国经济增长放缓带来的需求影响，油价小幅走低。纽约期货跌幅高达……</div></blockquote></p><p> <a href=\"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html\">网页链接</a> </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html\">网页连接</a></blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oil Slips on Growing Threat of Delta Variant to Demand<blockquote>德尔塔变异毒株对需求的威胁越来越大，油价下滑</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOil Slips on Growing Threat of Delta Variant to Demand<blockquote>德尔塔变异毒株对需求的威胁越来越大，油价下滑</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-07-12 23:03</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> (Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China. Futures in New York fell as much as ...</p><p><blockquote><div>（彭博社）——由于交易员努力应对 Covid-19 在多个地区卷土重来和中国经济增长放缓带来的需求影响，油价小幅走低。纽约期货跌幅高达……</div></blockquote></p><p> <a href=\"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html\">网页链接</a> </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/oil-extends-gains-investors-betting-224520271.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143990601","content_text":"(Bloomberg) -- Oil edged lower as traders grappled with the demand implications of a Covid-19 resurgence in several regions and slowing economic growth in China.\nFutures in New York fell as much as 1.9% on Monday. New mobility restrictions have been introduced in parts of Japan, South Korea and Vietnam to curb the spread of the delta variant, clouding the demand outlook for oil. Meanwhile, China’s economic rebound is reported to have slowed. A stronger U.S. dollar also weighed on prices, making commodities priced in the currency less attractive.\n“As the Covid-19 variant continues to hit Asia hard, which is really the key swing demand center, that’s a big, big negative for the complex,” said John Kilduff, a partner at Again Capital LLC.\nFuel consumption in economies such as the U.S. and China has boosted oil prices this year amid tight global supplies. OPEC and its allies have been unable to agree on a supply increase, creating volatility in the market and pushing crude to its first weekly loss since May last week. China’s slowing economic recovery and the spread of the delta variant may threaten the global demand for oil and the commodity’s trajectory so far this year.\nChina’s growth eased in the second quarter to 8% from the record gain of 18.3% in the first quarter, according to a Bloomberg poll of economists. Retail sales and industrial production are expected to moderate, too.\n“There is some weaker Chinese data, but also the rise of the delta variant in Europe is causing some doubts on the demand recovery,” said Hans van Cleef, senior energy economist at ABN Amro.\nThe delta variant has spread around the world, including in the U.S., which reported the most cases since mid-May. In Europe, officials in the U.K. and France are issuing warnings about new cases and reopenings.\nUncertainty over imminent supply from OPEC+ continues to loom over the market. The alliance abandoned meetings last week after a dispute between members over production cuts, and one week later, no deal is in sight.\n“They’re going to step up to a degree, it’s a matter of how much, and whether or not it falls apart,” said Kilduff of Again Capital LLC.\nThe International Energy Agency will provide investors with a snapshot of the market on Tuesday with the release of its monthly report, while OPEC will release its own monthly report on Thursday.","news_type":1,"symbols_score_info":{"CLmain":0.9}},"isVote":1,"tweetType":1,"viewCount":2178,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114481303,"gmtCreate":1623087740802,"gmtModify":1631889244259,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"title":"","htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/114481303","repostId":"1133110564","repostType":4,"repost":{"id":"1133110564","kind":"news","pubTimestamp":1623080895,"share":"https://www.laohunote.com/m/news/1133110564?lang=zh_CN&edition=full","pubTime":"2021-06-07 23:48","market":"us","language":"en","title":"Controversial Biogen Alzheimer Drug Wins FDA Approval<blockquote>备受争议的百健阿尔茨海默病药物获得 FDA 批准</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1133110564","media":"zerohedge","summary":"In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's ","content":"<p>In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's experimental drug for treating the physiological causes of Alzheimer's, as the first treatment to address an underlying cause of the disease despite the remaining controversy over the drug's decidedly mixed clinical trial results.</p><p><blockquote>FDA 周一批准了 Biogen 用于治疗阿尔茨海默病生理原因的实验性药物 Aduhelm (aducanumab)，这可能是对百健 (Biogen) 来说的一个重大政变，尽管该药物的临床试验结果明显好坏参半，但仍有争议。</blockquote></p><p> AsReutersexplains, Aduhelm is one of a long list of drugs that have aimed to remove sticky deposits of a protein called amyloid beta from the brains of patients suffering from early-stage Alzheimer's in order to stave off the worst ravages of the disease, which is characterized by severe memory loss and the loss of the ability to care for oneself.</p><p><blockquote>正如路透社解释的那样，Aduhelm 是一长串旨在清除早期阿尔茨海默氏症患者大脑中一种称为淀粉样蛋白 β 的蛋白质粘性沉积物的药物之一，以避免该疾病最严重的破坏，其特征是严重的记忆力丧失和丧失自理能力。</blockquote></p><p> The clinical trials for Aduhelm were the first to show that a reduction in these plaques (which are considered a hallmark symptom of the disease) can slow the clinical decline of a patient.</p><p><blockquote>Aduhelm的临床试验首次表明，这些斑块（被认为是该疾病的标志性症状）的减少可以减缓患者的临床下降。</blockquote></p><p> The drug has created a rift in the professional community that was mentioned inthe FDA's press release: the agency said that the data included in the Biogen's submission - which were derived from two phase 3 clinical trials - were \"highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.\" Many scientists opposed the drug's approval, saying it doesn't work.</p><p><blockquote>该药物在专业界造成了裂痕，FDA 的新闻稿中提到了这一点：该机构表示，百健提交的材料中包含的数据（来自两项 3 期临床试验）“非常复杂，在临床益处方面留下了剩余的不确定性。关于 Aduhelm 是否应该获得批准，公众一直存在相当大的争论。正如在解释科学数据时经常发生的那样，专家界提出了不同的观点”。许多科学家反对该药物的批准，称其不起作用。</blockquote></p><p> As a result, Biogen will be required to conduct another round of post-approval clinical studies (what the FDA is calling a \"Phase 4\" trial).</p><p><blockquote>因此，百健将被要求进行另一轮批准后的临床研究（FDA称之为“4期”试验）。</blockquote></p><p> Biogen's new drug is the first Alzheimer's treatment approved since 2003. Existing treatment courses for the disease don't do much to arrest the underlying causes, but rather are designed to make patients more comfortable.</p><p><blockquote>百健的新药是自2003年以来第一个被批准的阿尔茨海默病治疗药物。该疾病的现有治疗方案并没有起到多大作用来阻止潜在的原因，而是旨在让患者更舒适。</blockquote></p><p> FDA approved Aduhelm to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, which allowed for the drug's approval thanks to the success it showed in reducing the amyloid beta brain plaque.</p><p><blockquote>美国食品和药物管理局批准 Aduhelm 使用加速批准途径治疗阿尔茨海默病患者，由于该药物在减少β淀粉样蛋白脑斑块方面取得了成功，因此获得了批准。</blockquote></p><p> Shares of Biogen climbed on the news, as did shares in other companies known to be working on alzheimer treatments, including Biogen rival Eli Lilly. The Nasdaq biotech index climbed to a session high.</p><p><blockquote>这一消息传出后，百健的股价上涨，其他已知从事阿尔茨海默氏症治疗的公司的股价也随之上涨，其中包括百健的竞争对手礼来公司。纳斯达克生物技术指数攀升至盘中高点。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/ac26030030981a2daa2396729b972e22\" tg-width=\"500\" tg-height=\"337\"><u><b>Read the full press release below:</b></u></p><p><blockquote><u><b>阅读下面的完整新闻稿：</b></u></blockquote></p><p> <i>Today FDA approved Aduhelm (aducanumab) to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, under which the FDA approves a drug for a serious or life-threatening illness that may provide meaningful therapeutic benefit over existing treatments when the drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients and there remains some uncertainty about the drug’s clinical benefit.</i></p><p><blockquote><i>今天，美国食品和药物管理局批准了 Aduhelm（aducanumab），使用加速批准途径治疗阿尔茨海默病患者，根据该途径，美国食品和药物管理局批准了一种治疗严重或危及生命疾病的药物，如果该药物被证明对替代终点产生影响，且该药物的临床益处仍存在一些不确定性，则该药物可能比现有治疗提供有意义的治疗益处。</i></blockquote></p><p> <i>This approval is significant in many ways. Aduhelm is the first novel therapy approved for Alzheimer’s disease since 2003. Perhaps more significantly, Aduhelm is the first treatment directed at the underlying pathophysiology of Alzheimer’s disease, the presence of amyloid beta plaques in the brain. The clinical trials for Aduhelm were the first to show that a reduction in these plaques—a hallmark finding in the brain of patients with Alzheimer’s—is expected to lead to a reduction in the clinical decline of this devastating form of dementia.</i></p><p><blockquote><i>这一批准在很多方面都意义重大。Aduhelm 是自 2003 年以来获批治疗阿尔茨海默病的第一种新疗法。也许更重要的是，Aduhelm 是第一个针对阿尔茨海默病潜在病理生理学--大脑中存在 β 淀粉样蛋白斑块--的治疗方法。Aduhelm 的临床试验首次表明，这些斑块的减少--这是阿尔茨海默病患者大脑中的一个标志性发现--有望减少这种毁灭性痴呆症的临床下降。</i></blockquote></p><p> <i>We are well-aware of the attention surrounding this approval. We understand that Aduhelm has garnered the attention of the press, the Alzheimer’s patient community, our elected officials, and other interested stakeholders. With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review. Further, the data included in the applicant’s submission were highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.</i></p><p><blockquote><i>我们很清楚围绕这一批准的关注。我们了解到，Aduhelm 已经引起了媒体、阿尔茨海默氏症患者社区、我们的民选官员和其他相关利益相关者的关注。在对一种严重的、危及生命的疾病进行治疗的情况下，这么多人关注这篇综述的结果是有道理的。此外，申请人提交的材料中包含的数据非常复杂，在临床获益方面留下了剩余的不确定性。关于是否应该批准Aduhelm，公众进行了相当多的辩论。正如在解释科学数据时经常发生的那样，专家群体提供了不同的观点。</i></blockquote></p><p></p><p> <i>At the end of the day, we followed our usual course of action when making regulatory decisions in situations where the data are not straightforward. We examined the clinical trial findings with a fine-tooth comb, we solicited input from the Peripheral and Central Nervous System Drugs Advisory Committee, we listened to the perspectives of the patient community, and we reviewed all relevant data. We ultimately decided to use the Accelerated Approval pathway—a pathway intended to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need, and where there is an expectation of clinical benefit despite some residual uncertainty regarding that benefit. In determining that the application met the requirements for Accelerated Approval, the Agency concluded that the benefits of Aduhelm for patients with Alzheimer’s disease outweighed the risks of the therapy.</i></p><p><blockquote><i>归根结底，在数据不明确的情况下做出监管决策时，我们遵循了通常的行动方针。我们用细齿梳子检查了临床试验结果，我们征求了外周和中枢神经系统药物咨询委员会的意见，我们听取了患者群体的观点，我们审查了所有相关数据。我们最终决定使用加速审批途径——该途径旨在为严重疾病患者提供更早获得潜在有价值的疗法的途径，这些患者的需求未得到满足，并且尽管存在一些关于该益处的剩余不确定性，但仍有望获得临床益处。在确定该申请符合加速审批的要求时，该机构得出结论，Aduhelm 对阿尔茨海默病患者的益处大于该疗法的风险。</i></blockquote></p><p> <i><b>What the Data Show</b></i></p><p><blockquote><i><b>数据显示</b></i></blockquote></p><p> <i>The late-stage development program for Aduhelm consisted of two phase 3 clinical trials. One study met the primary endpoint, showing reduction in clinical decline. The second trial did not meet the primary endpoint. In all studies in which it was evaluated, however, Aduhelm consistently and very convincingly reduced the level of amyloid plaques in the brain in a dose- and time-dependent fashion. It is expected that the reduction in amyloid plaque will result in a reduction in clinical decline.</i></p><p><blockquote><i>Aduhelm的后期开发计划包括两项3期临床试验。一项研究达到了主要终点，显示临床下降减少。第二次试验未达到主要终点。然而，在所有评估它的研究中，Aduhelm以剂量和时间依赖性的方式持续且非常令人信服地降低了大脑中淀粉样蛋白斑块的水平。预期淀粉样蛋白斑块的减少将导致临床下降的减少。</i></blockquote></p><p> <i>We know that the Peripheral and Central Nervous System Drugs Advisory Committee, which convened in November 2020 to review the clinical trial data and discuss the evidence supporting the Aduhelm application, did not agree that it was reasonable to consider the clinical benefit of the one successful trial as the primary evidence supporting approval. The option of Accelerated Approval was not discussed by the Advisory Committee. As mentioned above, treatment with Aduhelm was clearly shown in all trials to substantially reduce amyloid beta plaques. This reduction in plaques is reasonably likely to result in clinical benefit. After the Advisory Committee provided its feedback, our review and deliberations continued, and we decided that the evidence presented in the Aduhelm application met the standard for Accelerated Approval. We thank the Advisory Committee for its independent review of the data and valuable advice.</i></p><p><blockquote><i>我们知道，外周和中枢神经系统药物咨询委员会于2020年11月召开会议，审查临床试验数据并讨论支持Aduhelm申请的证据，该委员会不同意将一项成功试验的临床获益视为支持批准的主要证据是合理的。咨询委员会没有讨论加速核准的备选办法。如上所述，用Aduhelm治疗在所有试验中都清楚地显示可显著减少β淀粉样蛋白斑块。这种斑块的减少合理地可能导致临床益处。在咨询委员会提供反馈后，我们继续进行审查和审议，我们决定Aduhelm申请中提出的证据符合加速批准的标准。我们感谢咨询委员会对数据的独立审查和宝贵意见。</i></blockquote></p><p> <i><b>Accelerated Approval</b></i></p><p><blockquote><i><b>加速审批</b></i></blockquote></p><p> <i>The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need. Approval is based on a surrogate or intermediate clinical endpoint (in this case reduction of amyloid plaque in the brain). A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.</i></p><p><blockquote><i>FDA制定了其加速批准计划，以允许早期批准治疗严重病症并满足未满足的医疗需求的药物。批准基于替代或中间临床终点（在这种情况下，减少大脑中的淀粉样蛋白斑块）。替代终点是标志物，例如实验室测量、放射线图像、物理标志或其他被认为预测临床益处但其本身不是临床益处的量度。使用替代终点可以大大缩短获得FDA批准所需的时间。</i></blockquote></p><p> <i>Drug companies are required to conduct post-approval studies to verify the anticipated clinical benefit. These studies are known as phase 4 confirmatory trials. If the confirmatory trial does not verify the drug’s anticipated clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.</i></p><p><blockquote><i>制药公司需要进行批准后研究，以验证预期的临床获益。这些研究被称为4期验证性试验。如果验证性试验没有验证该药物的预期临床益处，FDA 就会制定监管程序，这可能会导致该药物从市场上撤下。</i></blockquote></p><p> <i><b>The Devastation of Alzheimer’s Disease</b></i></p><p><blockquote><i><b>阿尔茨海默病的毁灭性</b></i></blockquote></p><p> <i>With all this said, we are extremely aware of the gradual and cumulative devastation that Alzheimer’s disease causes, as patients lose their memory and cognitive functioning over time. In late-stage disease, people can no longer hold a conversation or respond to their environment. On average, a person with Alzheimer’s disease lives four to eight years after diagnosis, but some patients can live up to 20 years with the disease.</i></p><p><blockquote><i>综上所述，我们非常清楚阿尔茨海默病会造成逐渐和累积的破坏，因为随着时间的推移，患者会失去记忆和认知功能。在疾病晚期，人们无法再进行对话或对环境做出反应。阿尔茨海默病患者在确诊后的平均寿命为四到八年，但有些患者的患病寿命可达 20 年。</i></blockquote></p><p> <i>The need for treatments is urgent: right now, more than 6 million Americans are living with Alzheimer’s disease and this number is expected to grow as the population ages. Alzheimer's is the sixth leading cause of death in the United States.</i></p><p><blockquote><i>治疗需求迫切： 目前，有 600 多万美国人患有阿尔茨海默病，随着人口老龄化，这一数字预计还会增加。阿尔茨海默氏症是美国第六大死因。</i></blockquote></p><p> <i>Although the Aduhelm data are complicated with respect to its clinical benefits, FDA has determined that there is substantial evidence that Aduhelm reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients. As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease.</i></p><p><blockquote><i>尽管Aduhelm的数据在其临床益处方面很复杂，但FDA已经确定有大量证据表明Aduhelm减少了大脑中的淀粉样β斑块，并且这些斑块的减少有合理的可能预测对患者的重要益处。由于 FDA 批准了 Aduhelm，阿尔茨海默病患者有了一种重要而关键的新疗法来帮助对抗这种疾病。</i></blockquote></p><p></p><p> <i>FDA will continue to monitor Aduhelm as it reaches the market and ultimately the patient’s bedside. Additionally, FDA is requiring Biogen to conduct a post-approval clinical trial to verify the drug’s clinical benefit. If the drug does not work as intended, we can take steps to remove it from the market. But hopefully, we will see further evidence of benefit in the clinical trial and as greater numbers of people receive Aduhelm. As an agency, we will also continue to work to foster drug development for this catastrophic disease.</i></p><p><blockquote><i>美国食品和药物管理局将继续对 Aduhelm 进行监控，直到它进入市场，并最终进入患者的床边。此外，美国食品和药物管理局还要求百健公司进行批准后临床试验，以验证该药物的临床益处。如果药物没有达到预期效果，我们可以采取措施将其从市场上撤下。但希望，随着越来越多的人接受Aduhelm，我们将在临床试验中看到更多的益处证据。作为一个机构，我们还将继续努力促进这种灾难性疾病的药物开发。</i></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Controversial Biogen Alzheimer Drug Wins FDA Approval<blockquote>备受争议的百健阿尔茨海默病药物获得 FDA 批准</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nControversial Biogen Alzheimer Drug Wins FDA Approval<blockquote>备受争议的百健阿尔茨海默病药物获得 FDA 批准</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">zerohedge</strong><span class=\"h-time small\">2021-06-07 23:48</span>\n</p>\n</h4>\n</header>\n<article>\n<p>In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's experimental drug for treating the physiological causes of Alzheimer's, as the first treatment to address an underlying cause of the disease despite the remaining controversy over the drug's decidedly mixed clinical trial results.</p><p><blockquote>FDA 周一批准了 Biogen 用于治疗阿尔茨海默病生理原因的实验性药物 Aduhelm (aducanumab)，这可能是对百健 (Biogen) 来说的一个重大政变，尽管该药物的临床试验结果明显好坏参半，但仍有争议。</blockquote></p><p> AsReutersexplains, Aduhelm is one of a long list of drugs that have aimed to remove sticky deposits of a protein called amyloid beta from the brains of patients suffering from early-stage Alzheimer's in order to stave off the worst ravages of the disease, which is characterized by severe memory loss and the loss of the ability to care for oneself.</p><p><blockquote>正如路透社解释的那样，Aduhelm 是一长串旨在清除早期阿尔茨海默氏症患者大脑中一种称为淀粉样蛋白 β 的蛋白质粘性沉积物的药物之一，以避免该疾病最严重的破坏，其特征是严重的记忆力丧失和丧失自理能力。</blockquote></p><p> The clinical trials for Aduhelm were the first to show that a reduction in these plaques (which are considered a hallmark symptom of the disease) can slow the clinical decline of a patient.</p><p><blockquote>Aduhelm的临床试验首次表明，这些斑块（被认为是该疾病的标志性症状）的减少可以减缓患者的临床下降。</blockquote></p><p> The drug has created a rift in the professional community that was mentioned inthe FDA's press release: the agency said that the data included in the Biogen's submission - which were derived from two phase 3 clinical trials - were \"highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.\" Many scientists opposed the drug's approval, saying it doesn't work.</p><p><blockquote>该药物在专业界造成了裂痕，FDA 的新闻稿中提到了这一点：该机构表示，百健提交的材料中包含的数据（来自两项 3 期临床试验）“非常复杂，在临床益处方面留下了剩余的不确定性。关于 Aduhelm 是否应该获得批准，公众一直存在相当大的争论。正如在解释科学数据时经常发生的那样，专家界提出了不同的观点”。许多科学家反对该药物的批准，称其不起作用。</blockquote></p><p> As a result, Biogen will be required to conduct another round of post-approval clinical studies (what the FDA is calling a \"Phase 4\" trial).</p><p><blockquote>因此，百健将被要求进行另一轮批准后的临床研究（FDA称之为“4期”试验）。</blockquote></p><p> Biogen's new drug is the first Alzheimer's treatment approved since 2003. Existing treatment courses for the disease don't do much to arrest the underlying causes, but rather are designed to make patients more comfortable.</p><p><blockquote>百健的新药是自2003年以来第一个被批准的阿尔茨海默病治疗药物。该疾病的现有治疗方案并没有起到多大作用来阻止潜在的原因，而是旨在让患者更舒适。</blockquote></p><p> FDA approved Aduhelm to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, which allowed for the drug's approval thanks to the success it showed in reducing the amyloid beta brain plaque.</p><p><blockquote>美国食品和药物管理局批准 Aduhelm 使用加速批准途径治疗阿尔茨海默病患者，由于该药物在减少β淀粉样蛋白脑斑块方面取得了成功，因此获得了批准。</blockquote></p><p> Shares of Biogen climbed on the news, as did shares in other companies known to be working on alzheimer treatments, including Biogen rival Eli Lilly. The Nasdaq biotech index climbed to a session high.</p><p><blockquote>这一消息传出后，百健的股价上涨，其他已知从事阿尔茨海默氏症治疗的公司的股价也随之上涨，其中包括百健的竞争对手礼来公司。纳斯达克生物技术指数攀升至盘中高点。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/ac26030030981a2daa2396729b972e22\" tg-width=\"500\" tg-height=\"337\"><u><b>Read the full press release below:</b></u></p><p><blockquote><u><b>阅读下面的完整新闻稿：</b></u></blockquote></p><p> <i>Today FDA approved Aduhelm (aducanumab) to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, under which the FDA approves a drug for a serious or life-threatening illness that may provide meaningful therapeutic benefit over existing treatments when the drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients and there remains some uncertainty about the drug’s clinical benefit.</i></p><p><blockquote><i>今天，美国食品和药物管理局批准了 Aduhelm（aducanumab），使用加速批准途径治疗阿尔茨海默病患者，根据该途径，美国食品和药物管理局批准了一种治疗严重或危及生命疾病的药物，如果该药物被证明对替代终点产生影响，且该药物的临床益处仍存在一些不确定性，则该药物可能比现有治疗提供有意义的治疗益处。</i></blockquote></p><p> <i>This approval is significant in many ways. Aduhelm is the first novel therapy approved for Alzheimer’s disease since 2003. Perhaps more significantly, Aduhelm is the first treatment directed at the underlying pathophysiology of Alzheimer’s disease, the presence of amyloid beta plaques in the brain. The clinical trials for Aduhelm were the first to show that a reduction in these plaques—a hallmark finding in the brain of patients with Alzheimer’s—is expected to lead to a reduction in the clinical decline of this devastating form of dementia.</i></p><p><blockquote><i>这一批准在很多方面都意义重大。Aduhelm 是自 2003 年以来获批治疗阿尔茨海默病的第一种新疗法。也许更重要的是，Aduhelm 是第一个针对阿尔茨海默病潜在病理生理学--大脑中存在 β 淀粉样蛋白斑块--的治疗方法。Aduhelm 的临床试验首次表明，这些斑块的减少--这是阿尔茨海默病患者大脑中的一个标志性发现--有望减少这种毁灭性痴呆症的临床下降。</i></blockquote></p><p> <i>We are well-aware of the attention surrounding this approval. We understand that Aduhelm has garnered the attention of the press, the Alzheimer’s patient community, our elected officials, and other interested stakeholders. With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review. Further, the data included in the applicant’s submission were highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.</i></p><p><blockquote><i>我们很清楚围绕这一批准的关注。我们了解到，Aduhelm 已经引起了媒体、阿尔茨海默氏症患者社区、我们的民选官员和其他相关利益相关者的关注。在对一种严重的、危及生命的疾病进行治疗的情况下，这么多人关注这篇综述的结果是有道理的。此外，申请人提交的材料中包含的数据非常复杂，在临床获益方面留下了剩余的不确定性。关于是否应该批准Aduhelm，公众进行了相当多的辩论。正如在解释科学数据时经常发生的那样，专家群体提供了不同的观点。</i></blockquote></p><p></p><p> <i>At the end of the day, we followed our usual course of action when making regulatory decisions in situations where the data are not straightforward. We examined the clinical trial findings with a fine-tooth comb, we solicited input from the Peripheral and Central Nervous System Drugs Advisory Committee, we listened to the perspectives of the patient community, and we reviewed all relevant data. We ultimately decided to use the Accelerated Approval pathway—a pathway intended to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need, and where there is an expectation of clinical benefit despite some residual uncertainty regarding that benefit. In determining that the application met the requirements for Accelerated Approval, the Agency concluded that the benefits of Aduhelm for patients with Alzheimer’s disease outweighed the risks of the therapy.</i></p><p><blockquote><i>归根结底，在数据不明确的情况下做出监管决策时，我们遵循了通常的行动方针。我们用细齿梳子检查了临床试验结果，我们征求了外周和中枢神经系统药物咨询委员会的意见，我们听取了患者群体的观点，我们审查了所有相关数据。我们最终决定使用加速审批途径——该途径旨在为严重疾病患者提供更早获得潜在有价值的疗法的途径，这些患者的需求未得到满足，并且尽管存在一些关于该益处的剩余不确定性，但仍有望获得临床益处。在确定该申请符合加速审批的要求时，该机构得出结论，Aduhelm 对阿尔茨海默病患者的益处大于该疗法的风险。</i></blockquote></p><p> <i><b>What the Data Show</b></i></p><p><blockquote><i><b>数据显示</b></i></blockquote></p><p> <i>The late-stage development program for Aduhelm consisted of two phase 3 clinical trials. One study met the primary endpoint, showing reduction in clinical decline. The second trial did not meet the primary endpoint. In all studies in which it was evaluated, however, Aduhelm consistently and very convincingly reduced the level of amyloid plaques in the brain in a dose- and time-dependent fashion. It is expected that the reduction in amyloid plaque will result in a reduction in clinical decline.</i></p><p><blockquote><i>Aduhelm的后期开发计划包括两项3期临床试验。一项研究达到了主要终点，显示临床下降减少。第二次试验未达到主要终点。然而，在所有评估它的研究中，Aduhelm以剂量和时间依赖性的方式持续且非常令人信服地降低了大脑中淀粉样蛋白斑块的水平。预期淀粉样蛋白斑块的减少将导致临床下降的减少。</i></blockquote></p><p> <i>We know that the Peripheral and Central Nervous System Drugs Advisory Committee, which convened in November 2020 to review the clinical trial data and discuss the evidence supporting the Aduhelm application, did not agree that it was reasonable to consider the clinical benefit of the one successful trial as the primary evidence supporting approval. The option of Accelerated Approval was not discussed by the Advisory Committee. As mentioned above, treatment with Aduhelm was clearly shown in all trials to substantially reduce amyloid beta plaques. This reduction in plaques is reasonably likely to result in clinical benefit. After the Advisory Committee provided its feedback, our review and deliberations continued, and we decided that the evidence presented in the Aduhelm application met the standard for Accelerated Approval. We thank the Advisory Committee for its independent review of the data and valuable advice.</i></p><p><blockquote><i>我们知道，外周和中枢神经系统药物咨询委员会于2020年11月召开会议，审查临床试验数据并讨论支持Aduhelm申请的证据，该委员会不同意将一项成功试验的临床获益视为支持批准的主要证据是合理的。咨询委员会没有讨论加速核准的备选办法。如上所述，用Aduhelm治疗在所有试验中都清楚地显示可显著减少β淀粉样蛋白斑块。这种斑块的减少合理地可能导致临床益处。在咨询委员会提供反馈后，我们继续进行审查和审议，我们决定Aduhelm申请中提出的证据符合加速批准的标准。我们感谢咨询委员会对数据的独立审查和宝贵意见。</i></blockquote></p><p> <i><b>Accelerated Approval</b></i></p><p><blockquote><i><b>加速审批</b></i></blockquote></p><p> <i>The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need. Approval is based on a surrogate or intermediate clinical endpoint (in this case reduction of amyloid plaque in the brain). A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.</i></p><p><blockquote><i>FDA制定了其加速批准计划，以允许早期批准治疗严重病症并满足未满足的医疗需求的药物。批准基于替代或中间临床终点（在这种情况下，减少大脑中的淀粉样蛋白斑块）。替代终点是标志物，例如实验室测量、放射线图像、物理标志或其他被认为预测临床益处但其本身不是临床益处的量度。使用替代终点可以大大缩短获得FDA批准所需的时间。</i></blockquote></p><p> <i>Drug companies are required to conduct post-approval studies to verify the anticipated clinical benefit. These studies are known as phase 4 confirmatory trials. If the confirmatory trial does not verify the drug’s anticipated clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.</i></p><p><blockquote><i>制药公司需要进行批准后研究，以验证预期的临床获益。这些研究被称为4期验证性试验。如果验证性试验没有验证该药物的预期临床益处，FDA 就会制定监管程序，这可能会导致该药物从市场上撤下。</i></blockquote></p><p> <i><b>The Devastation of Alzheimer’s Disease</b></i></p><p><blockquote><i><b>阿尔茨海默病的毁灭性</b></i></blockquote></p><p> <i>With all this said, we are extremely aware of the gradual and cumulative devastation that Alzheimer’s disease causes, as patients lose their memory and cognitive functioning over time. In late-stage disease, people can no longer hold a conversation or respond to their environment. On average, a person with Alzheimer’s disease lives four to eight years after diagnosis, but some patients can live up to 20 years with the disease.</i></p><p><blockquote><i>综上所述，我们非常清楚阿尔茨海默病会造成逐渐和累积的破坏，因为随着时间的推移，患者会失去记忆和认知功能。在疾病晚期，人们无法再进行对话或对环境做出反应。阿尔茨海默病患者在确诊后的平均寿命为四到八年，但有些患者的患病寿命可达 20 年。</i></blockquote></p><p> <i>The need for treatments is urgent: right now, more than 6 million Americans are living with Alzheimer’s disease and this number is expected to grow as the population ages. Alzheimer's is the sixth leading cause of death in the United States.</i></p><p><blockquote><i>治疗需求迫切： 目前，有 600 多万美国人患有阿尔茨海默病，随着人口老龄化，这一数字预计还会增加。阿尔茨海默氏症是美国第六大死因。</i></blockquote></p><p> <i>Although the Aduhelm data are complicated with respect to its clinical benefits, FDA has determined that there is substantial evidence that Aduhelm reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients. As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease.</i></p><p><blockquote><i>尽管Aduhelm的数据在其临床益处方面很复杂，但FDA已经确定有大量证据表明Aduhelm减少了大脑中的淀粉样β斑块，并且这些斑块的减少有合理的可能预测对患者的重要益处。由于 FDA 批准了 Aduhelm，阿尔茨海默病患者有了一种重要而关键的新疗法来帮助对抗这种疾病。</i></blockquote></p><p></p><p> <i>FDA will continue to monitor Aduhelm as it reaches the market and ultimately the patient’s bedside. Additionally, FDA is requiring Biogen to conduct a post-approval clinical trial to verify the drug’s clinical benefit. If the drug does not work as intended, we can take steps to remove it from the market. But hopefully, we will see further evidence of benefit in the clinical trial and as greater numbers of people receive Aduhelm. As an agency, we will also continue to work to foster drug development for this catastrophic disease.</i></p><p><blockquote><i>美国食品和药物管理局将继续对 Aduhelm 进行监控，直到它进入市场，并最终进入患者的床边。此外，美国食品和药物管理局还要求百健公司进行批准后临床试验，以验证该药物的临床益处。如果药物没有达到预期效果，我们可以采取措施将其从市场上撤下。但希望，随着越来越多的人接受Aduhelm，我们将在临床试验中看到更多的益处证据。作为一个机构，我们还将继续努力促进这种灾难性疾病的药物开发。</i></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.zerohedge.com/markets/breakthrough-biogen-alzheimer-drug-wins-fda-approval?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29\">zerohedge</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.zerohedge.com/markets/breakthrough-biogen-alzheimer-drug-wins-fda-approval?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133110564","content_text":"In what could be a major coup for Biogen, the FDA on Monday approved Aduhelm (aducanumab), Biogen's experimental drug for treating the physiological causes of Alzheimer's, as the first treatment to address an underlying cause of the disease despite the remaining controversy over the drug's decidedly mixed clinical trial results.\nAsReutersexplains, Aduhelm is one of a long list of drugs that have aimed to remove sticky deposits of a protein called amyloid beta from the brains of patients suffering from early-stage Alzheimer's in order to stave off the worst ravages of the disease, which is characterized by severe memory loss and the loss of the ability to care for oneself.\nThe clinical trials for Aduhelm were the first to show that a reduction in these plaques (which are considered a hallmark symptom of the disease) can slow the clinical decline of a patient.\nThe drug has created a rift in the professional community that was mentioned inthe FDA's press release: the agency said that the data included in the Biogen's submission - which were derived from two phase 3 clinical trials - were \"highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.\" Many scientists opposed the drug's approval, saying it doesn't work.\nAs a result, Biogen will be required to conduct another round of post-approval clinical studies (what the FDA is calling a \"Phase 4\" trial).\nBiogen's new drug is the first Alzheimer's treatment approved since 2003. Existing treatment courses for the disease don't do much to arrest the underlying causes, but rather are designed to make patients more comfortable.\nFDA approved Aduhelm to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, which allowed for the drug's approval thanks to the success it showed in reducing the amyloid beta brain plaque.\nShares of Biogen climbed on the news, as did shares in other companies known to be working on alzheimer treatments, including Biogen rival Eli Lilly. The Nasdaq biotech index climbed to a session high.\nRead the full press release below:\nToday FDA approved Aduhelm (aducanumab) to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, under which the FDA approves a drug for a serious or life-threatening illness that may provide meaningful therapeutic benefit over existing treatments when the drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients and there remains some uncertainty about the drug’s clinical benefit.\nThis approval is significant in many ways. Aduhelm is the first novel therapy approved for Alzheimer’s disease since 2003. Perhaps more significantly, Aduhelm is the first treatment directed at the underlying pathophysiology of Alzheimer’s disease, the presence of amyloid beta plaques in the brain. The clinical trials for Aduhelm were the first to show that a reduction in these plaques—a hallmark finding in the brain of patients with Alzheimer’s—is expected to lead to a reduction in the clinical decline of this devastating form of dementia.\nWe are well-aware of the attention surrounding this approval. We understand that Aduhelm has garnered the attention of the press, the Alzheimer’s patient community, our elected officials, and other interested stakeholders. With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review. Further, the data included in the applicant’s submission were highly complex and left residual uncertainties regarding clinical benefit. There has been considerable public debate on whether Aduhelm should be approved. As is often the case when it comes to interpreting scientific data, the expert community has offered differing perspectives.\nAt the end of the day, we followed our usual course of action when making regulatory decisions in situations where the data are not straightforward. We examined the clinical trial findings with a fine-tooth comb, we solicited input from the Peripheral and Central Nervous System Drugs Advisory Committee, we listened to the perspectives of the patient community, and we reviewed all relevant data. We ultimately decided to use the Accelerated Approval pathway—a pathway intended to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need, and where there is an expectation of clinical benefit despite some residual uncertainty regarding that benefit. In determining that the application met the requirements for Accelerated Approval, the Agency concluded that the benefits of Aduhelm for patients with Alzheimer’s disease outweighed the risks of the therapy.\nWhat the Data Show\nThe late-stage development program for Aduhelm consisted of two phase 3 clinical trials. One study met the primary endpoint, showing reduction in clinical decline. The second trial did not meet the primary endpoint. In all studies in which it was evaluated, however, Aduhelm consistently and very convincingly reduced the level of amyloid plaques in the brain in a dose- and time-dependent fashion. It is expected that the reduction in amyloid plaque will result in a reduction in clinical decline.\nWe know that the Peripheral and Central Nervous System Drugs Advisory Committee, which convened in November 2020 to review the clinical trial data and discuss the evidence supporting the Aduhelm application, did not agree that it was reasonable to consider the clinical benefit of the one successful trial as the primary evidence supporting approval. The option of Accelerated Approval was not discussed by the Advisory Committee. As mentioned above, treatment with Aduhelm was clearly shown in all trials to substantially reduce amyloid beta plaques. This reduction in plaques is reasonably likely to result in clinical benefit. After the Advisory Committee provided its feedback, our review and deliberations continued, and we decided that the evidence presented in the Aduhelm application met the standard for Accelerated Approval. We thank the Advisory Committee for its independent review of the data and valuable advice.\nAccelerated Approval\nThe FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need. Approval is based on a surrogate or intermediate clinical endpoint (in this case reduction of amyloid plaque in the brain). A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.\nDrug companies are required to conduct post-approval studies to verify the anticipated clinical benefit. These studies are known as phase 4 confirmatory trials. If the confirmatory trial does not verify the drug’s anticipated clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.\nThe Devastation of Alzheimer’s Disease\nWith all this said, we are extremely aware of the gradual and cumulative devastation that Alzheimer’s disease causes, as patients lose their memory and cognitive functioning over time. In late-stage disease, people can no longer hold a conversation or respond to their environment. On average, a person with Alzheimer’s disease lives four to eight years after diagnosis, but some patients can live up to 20 years with the disease.\nThe need for treatments is urgent: right now, more than 6 million Americans are living with Alzheimer’s disease and this number is expected to grow as the population ages. Alzheimer's is the sixth leading cause of death in the United States.\nAlthough the Aduhelm data are complicated with respect to its clinical benefits, FDA has determined that there is substantial evidence that Aduhelm reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients. As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease.\nFDA will continue to monitor Aduhelm as it reaches the market and ultimately the patient’s bedside. Additionally, FDA is requiring Biogen to conduct a post-approval clinical trial to verify the drug’s clinical benefit. If the drug does not work as intended, we can take steps to remove it from the market. But hopefully, we will see further evidence of benefit in the clinical trial and as greater numbers of people receive Aduhelm. As an agency, we will also continue to work to foster drug development for this catastrophic disease.","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":3328,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":118594655,"gmtCreate":1622736920377,"gmtModify":1631889244270,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"title":"","htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/118594655","repostId":"2140247164","repostType":4,"isVote":1,"tweetType":1,"viewCount":2769,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":111320436,"gmtCreate":1622653635125,"gmtModify":1631889244285,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"title":"","htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/111320436","repostId":"2140448417","repostType":4,"isVote":1,"tweetType":1,"viewCount":3478,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":111963117,"gmtCreate":1622649396339,"gmtModify":1631889244292,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"title":"","htmlText":". ","listText":". ","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/111963117","repostId":"1188552613","repostType":4,"repost":{"id":"1188552613","kind":"news","pubTimestamp":1622627641,"share":"https://www.laohunote.com/m/news/1188552613?lang=zh_CN&edition=full","pubTime":"2021-06-02 17:54","market":"us","language":"en","title":"AMC Stock Is Surging Again. How to Make Sense of the Move.<blockquote>AMC 股价再次飙升。如何理解这一举动？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1188552613","media":"Barrons","summary":"AMC Entertainment‘s skyrocketing stock price would be easy to dismiss as just meme-trade madness, th","content":"<p>AMC Entertainment‘s skyrocketing stock price would be easy to dismiss as just meme-trade madness, that social media-fueled investor frenzy that has launched the likes of GameStop and BlackBerry into speculative territory.</p><p><blockquote>AMC院线飙升的股价很容易被视为只是迷因交易的疯狂，这种社交媒体引发的投资者狂热已经将游戏驿站和黑莓等公司推入了投机领域。</blockquote></p><p> But it’s possible that traditional investors have missed a fundamental change in the movie theater business—and it wouldn’t be the first time.</p><p><blockquote>但传统投资者有可能错过了电影院行业的根本性变革--这也不是第一次了。</blockquote></p><p> Shares of AMC (ticker: AMC) surged 23% on Tuesday, closing at $32.04—just off an all-time high of $36.72 set in late May. That puts the movie-theater chain’s market capitalization at roughly $16 billion, more than 15 times what it was in 2018, a record-breaking year at the box office. Shares were up another 34%, to $42.92, in premarket trading Wednesday.</p><p><blockquote>AMC（股票代码：AMC）股价周二飙升 23%，收于 32.04 美元，略低于 5 月下旬创下的 36.72 美元的历史高点。这使得这家连锁影院的市值约为 160 亿美元，是 2018 年的 15 倍多，2018 年是票房创纪录的一年。在周三的盘前交易中，该公司股价又上涨了 34%，至 42.92 美元。</blockquote></p><p> Even if investors missed an inflection point, though, the math doesn’t add up. The reason might be that market cap isn’t the right measure. Maybe it’s enterprise value, which is essentially market cap and debt. AMC’s enterprise value is about $26 billion, compared with $6.2 billion or so at the end of 2018.</p><p><blockquote>不过，即使投资者错过了拐点，数学也不会相加。原因可能是市值不是正确的衡量标准。也许是企业价值，本质上就是市值和债务。AMC 的企业价值约为 260 亿美元，而 2018 年底约为 62 亿美元。</blockquote></p><p> AMC added debt during the pandemic as theaters in the country’s biggest cities were dark for months. And the numbers make it easy to understand why: The U.S. box office in 2020 generated about $2.1 billion in ticket sales, down 81% from the 2018 record of $11.9 billion.</p><p><blockquote>由于全国最大城市的影院几个月来一直处于黑暗状态，AMC 在大流行病期间增加了债务。这些数字很容易理解为什么：2020年美国票房产生了约21亿美元的门票销售额，比2018年创纪录的119亿美元下降了81%。</blockquote></p><p> So, it seems investors have been vexed by movie theater economics. But it wouldn’t be the first time. The industry essentially went belly up at the turn of the millennium. Regal Cinemas, for instance, declared bankruptcy in 2001.</p><p><blockquote>因此，投资者似乎对电影院经济感到困扰。但这并不是第一次。这个行业在千禧年之交基本上崩溃了。例如，富豪影院于2001年宣布破产。</blockquote></p><p> Back then, the industry had plenty of capacity because of a new theater design—stadium seating that gave a better view of the screen. That shift meant movie theater chains had to renovate or risk losing all their patrons to movie theaters that offered the better view. In the end, too many seats and not enough patrons meant the return on the stadium-seating investments never materialized.</p><p><blockquote>当时，由于一种新的剧院设计——体育场座椅可以提供更好的屏幕视野，该行业有足够的容量。这种转变意味着连锁电影院不得不翻新，否则就有可能失去所有顾客，转而去视野更好的电影院。最终，太多的座位和不够的顾客意味着体育场座位投资的回报从未实现。</blockquote></p><p> The upshot was consolidation. With fewer operators, the number of screens stabilized. Between 2002 and 2007, Regal Cinemas became a cash-generating machine because the stock was mispriced. The stock returned 21% a year on average. The S&P 500 and Dow Jones Industrial Average both returned less than 9% a year on average over the same period.</p><p><blockquote>结果是整合。随着操作员的减少，屏幕数量趋于稳定。2002年至2007年间，富豪影院成为一台赚钱机器，因为股票定价错误。该股平均年回报率为 21%。同期，标普500和道琼斯工业平均指数的平均年回报率均低于 9%。</blockquote></p><p> In those days, Regal Cinema’s enterprise value about $5 billion, or about 50% of total U.S. box office sales. That’s far short of AMC today. Something new has to be different for AMC to be worth it.</p><p><blockquote>当时，富豪影院的企业价值约为 50 亿美元，约占美国总票房的 50%。这与今天的 AMC 相去甚远。对于 AMC 来说，新的东西必须与众不同才有价值。</blockquote></p><p> Maybe the movie theater business is going to go through another period of consolidation, which can usher in another golden age of returns. AMC’s Tuesday gains, in fact, were catalyzed by new capital raised so the company could go on the offensive, acquiring defunct chains. Monopolies, after all, can be good for stock returns.</p><p><blockquote>或许影院业务又将经历一段盘整期，或许会迎来另一个回报的黄金时代。事实上，AMC 周二的涨幅是由新筹集的资金推动的，这样该公司就可以发动攻势，收购倒闭的连锁店。毕竟，垄断有利于股票回报。</blockquote></p><p> If AMC can increase market share and the U.S. box office sales can return to 2018 levels in a few years, total sales at might be $9 billion—$6 billion from tickets and $3 billion from concessions. Sales in 2018 amounted to $5.5 billion.</p><p><blockquote>如果AMC能够增加市场份额，并且美国票房能够在几年内恢复到2018年的水平，at的总销售额可能达到90亿美元——60亿美元来自门票，30亿美元来自特许经营。2018年销售额达55亿美元。</blockquote></p><p> Then, with better gross profit margins derived from larger scale, AMC might be able to generate $600 million in free cash flow annually, which puts the stock at about a 4% free cash flow yield. The S&P 500 trades for about a 3% free cash flow yield. The numbers can work—if they’re stretched.</p><p><blockquote>然后，凭借更大的规模带来的更好的毛利率，AMC 每年可能能够产生 6 亿美元的自由现金流，这使得该股的自由现金流收益率约为 4%。标普500的自由现金流收益率约为 3%。这些数字是可以起作用的--如果它们被拉伸的话。</blockquote></p><p> There are problems with this scenario, though. There are lots of ifs and mights—and AMC has never generated cash flow like that in the past. Arriving at $600 million in free cash flow is more about justifying current valuations than predicting what is likely.</p><p><blockquote>不过，这种情况也存在问题。有很多如果和可能——而 AMC 过去从未产生过这样的现金流。达到 6 亿美元的自由现金流更多的是为了证明当前估值的合理性，而不是预测可能发生的情况。</blockquote></p><p> Also, with mergers and acquisitions, AMC market shares might rise, but there are still competitors. Regal Cinemas is still out there, owned by Cineworld Holdings (CINE. London). So is Cinemark (CNK). There’s not a true monopoly.</p><p><blockquote>此外，随着并购，AMC 市场份额可能会上升，但仍然存在竞争对手。富豪影院仍然存在，由电影世界控股公司（Cine.London）所有。Cinemark (CNK) 也是。不存在真正的垄断。</blockquote></p><p> AMC and its peers have to deal with streaming, too. Windows for exclusive theater showings are shrinking. The pandemic has accelerated that. And if AMC gets too large and demanding for movie makers, the talent can always go to streaming faster, hurting box office sales.</p><p><blockquote>AMC 及其同行也必须处理流媒体问题。独家影院放映的窗口正在缩小。疫情加速了这一进程。如果AMC变得太大，对电影制作人的要求太高，人才总是可以更快地流向流媒体，从而损害票房销售。</blockquote></p><p> There is also the problem of the peer stocks. They aren’t trading like this is a brave new world for theaters. Cineworld stock is up 484% from its 52-week low, but shares are still off 72% from all-time highs. Cinemark shares are up 222% from their 52-week low. They are down 47% from their all-time high.</p><p><blockquote>还有同行股的问题。他们不会像这样交易，这对剧院来说是一个勇敢的新世界。Cineworld 股价较 52 周低点上涨 484%，但仍较历史高点下跌 72%。Cinemark 股价较 52 周低点上涨 222%。它们比历史高点下降了47%。</blockquote></p><p> AMC stock, again, is up almost 1,600% from its 52-week low and is down just 13% from its May all-time high.</p><p><blockquote>AMC 股价再次较 52 周低点上涨近 1,600%，较 5 月份的历史高点仅下跌 13%。</blockquote></p><p> Wall Street just doesn’t see the potential either. Nine analysts cover the stock. The average analyst price target is about $5. Before the pandemic, the average analyst price target was $15. But there were fewer shares back then. The old target enterprise value was roughly $7 billion. It’s tough to get from $7 billion to $26 billion predicting better margins.</p><p><blockquote>华尔街也看不到这种潜力。九名分析师研究了该股。分析师的平均目标价约为 5 美元。在大流行之前，分析师的平均目标价为 15 美元。但当时的股份较少。旧目标企业价值约为70亿美元。从 70 亿美元到 260 亿美元很难预测更好的利润率。</blockquote></p><p></p><p> Analysts do have positive free cash flow modeled, though–$13 million in 2022 and $90 million in 2023. That’s a long way from $600 million.</p><p><blockquote>不过，分析师确实模拟了正的自由现金流——2022 年为 1300 万美元，2023 年为 9000 万美元。这距离 6 亿美元还有很长的路要走。</blockquote></p><p> And that’s just another way of saying that AMC bulls are a long way from making the math work.</p><p><blockquote>这只是另一种说法，即 AMC 看涨者离计算成功还有很长的路要走。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC Stock Is Surging Again. How to Make Sense of the Move.<blockquote>AMC 股价再次飙升。如何理解这一举动？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC Stock Is Surging Again. How to Make Sense of the Move.<blockquote>AMC 股价再次飙升。如何理解这一举动？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-06-02 17:54</span>\n</p>\n</h4>\n</header>\n<article>\n<p>AMC Entertainment‘s skyrocketing stock price would be easy to dismiss as just meme-trade madness, that social media-fueled investor frenzy that has launched the likes of GameStop and BlackBerry into speculative territory.</p><p><blockquote>AMC院线飙升的股价很容易被视为只是迷因交易的疯狂，这种社交媒体引发的投资者狂热已经将游戏驿站和黑莓等公司推入了投机领域。</blockquote></p><p> But it’s possible that traditional investors have missed a fundamental change in the movie theater business—and it wouldn’t be the first time.</p><p><blockquote>但传统投资者有可能错过了电影院行业的根本性变革--这也不是第一次了。</blockquote></p><p> Shares of AMC (ticker: AMC) surged 23% on Tuesday, closing at $32.04—just off an all-time high of $36.72 set in late May. That puts the movie-theater chain’s market capitalization at roughly $16 billion, more than 15 times what it was in 2018, a record-breaking year at the box office. Shares were up another 34%, to $42.92, in premarket trading Wednesday.</p><p><blockquote>AMC（股票代码：AMC）股价周二飙升 23%，收于 32.04 美元，略低于 5 月下旬创下的 36.72 美元的历史高点。这使得这家连锁影院的市值约为 160 亿美元，是 2018 年的 15 倍多，2018 年是票房创纪录的一年。在周三的盘前交易中，该公司股价又上涨了 34%，至 42.92 美元。</blockquote></p><p> Even if investors missed an inflection point, though, the math doesn’t add up. The reason might be that market cap isn’t the right measure. Maybe it’s enterprise value, which is essentially market cap and debt. AMC’s enterprise value is about $26 billion, compared with $6.2 billion or so at the end of 2018.</p><p><blockquote>不过，即使投资者错过了拐点，数学也不会相加。原因可能是市值不是正确的衡量标准。也许是企业价值，本质上就是市值和债务。AMC 的企业价值约为 260 亿美元，而 2018 年底约为 62 亿美元。</blockquote></p><p> AMC added debt during the pandemic as theaters in the country’s biggest cities were dark for months. And the numbers make it easy to understand why: The U.S. box office in 2020 generated about $2.1 billion in ticket sales, down 81% from the 2018 record of $11.9 billion.</p><p><blockquote>由于全国最大城市的影院几个月来一直处于黑暗状态，AMC 在大流行病期间增加了债务。这些数字很容易理解为什么：2020年美国票房产生了约21亿美元的门票销售额，比2018年创纪录的119亿美元下降了81%。</blockquote></p><p> So, it seems investors have been vexed by movie theater economics. But it wouldn’t be the first time. The industry essentially went belly up at the turn of the millennium. Regal Cinemas, for instance, declared bankruptcy in 2001.</p><p><blockquote>因此，投资者似乎对电影院经济感到困扰。但这并不是第一次。这个行业在千禧年之交基本上崩溃了。例如，富豪影院于2001年宣布破产。</blockquote></p><p> Back then, the industry had plenty of capacity because of a new theater design—stadium seating that gave a better view of the screen. That shift meant movie theater chains had to renovate or risk losing all their patrons to movie theaters that offered the better view. In the end, too many seats and not enough patrons meant the return on the stadium-seating investments never materialized.</p><p><blockquote>当时，由于一种新的剧院设计——体育场座椅可以提供更好的屏幕视野，该行业有足够的容量。这种转变意味着连锁电影院不得不翻新，否则就有可能失去所有顾客，转而去视野更好的电影院。最终，太多的座位和不够的顾客意味着体育场座位投资的回报从未实现。</blockquote></p><p> The upshot was consolidation. With fewer operators, the number of screens stabilized. Between 2002 and 2007, Regal Cinemas became a cash-generating machine because the stock was mispriced. The stock returned 21% a year on average. The S&P 500 and Dow Jones Industrial Average both returned less than 9% a year on average over the same period.</p><p><blockquote>结果是整合。随着操作员的减少，屏幕数量趋于稳定。2002年至2007年间，富豪影院成为一台赚钱机器，因为股票定价错误。该股平均年回报率为 21%。同期，标普500和道琼斯工业平均指数的平均年回报率均低于 9%。</blockquote></p><p> In those days, Regal Cinema’s enterprise value about $5 billion, or about 50% of total U.S. box office sales. That’s far short of AMC today. Something new has to be different for AMC to be worth it.</p><p><blockquote>当时，富豪影院的企业价值约为 50 亿美元，约占美国总票房的 50%。这与今天的 AMC 相去甚远。对于 AMC 来说，新的东西必须与众不同才有价值。</blockquote></p><p> Maybe the movie theater business is going to go through another period of consolidation, which can usher in another golden age of returns. AMC’s Tuesday gains, in fact, were catalyzed by new capital raised so the company could go on the offensive, acquiring defunct chains. Monopolies, after all, can be good for stock returns.</p><p><blockquote>或许影院业务又将经历一段盘整期，或许会迎来另一个回报的黄金时代。事实上，AMC 周二的涨幅是由新筹集的资金推动的，这样该公司就可以发动攻势，收购倒闭的连锁店。毕竟，垄断有利于股票回报。</blockquote></p><p> If AMC can increase market share and the U.S. box office sales can return to 2018 levels in a few years, total sales at might be $9 billion—$6 billion from tickets and $3 billion from concessions. Sales in 2018 amounted to $5.5 billion.</p><p><blockquote>如果AMC能够增加市场份额，并且美国票房能够在几年内恢复到2018年的水平，at的总销售额可能达到90亿美元——60亿美元来自门票，30亿美元来自特许经营。2018年销售额达55亿美元。</blockquote></p><p> Then, with better gross profit margins derived from larger scale, AMC might be able to generate $600 million in free cash flow annually, which puts the stock at about a 4% free cash flow yield. The S&P 500 trades for about a 3% free cash flow yield. The numbers can work—if they’re stretched.</p><p><blockquote>然后，凭借更大的规模带来的更好的毛利率，AMC 每年可能能够产生 6 亿美元的自由现金流，这使得该股的自由现金流收益率约为 4%。标普500的自由现金流收益率约为 3%。这些数字是可以起作用的--如果它们被拉伸的话。</blockquote></p><p> There are problems with this scenario, though. There are lots of ifs and mights—and AMC has never generated cash flow like that in the past. Arriving at $600 million in free cash flow is more about justifying current valuations than predicting what is likely.</p><p><blockquote>不过，这种情况也存在问题。有很多如果和可能——而 AMC 过去从未产生过这样的现金流。达到 6 亿美元的自由现金流更多的是为了证明当前估值的合理性，而不是预测可能发生的情况。</blockquote></p><p> Also, with mergers and acquisitions, AMC market shares might rise, but there are still competitors. Regal Cinemas is still out there, owned by Cineworld Holdings (CINE. London). So is Cinemark (CNK). There’s not a true monopoly.</p><p><blockquote>此外，随着并购，AMC 市场份额可能会上升，但仍然存在竞争对手。富豪影院仍然存在，由电影世界控股公司（Cine.London）所有。Cinemark (CNK) 也是。不存在真正的垄断。</blockquote></p><p> AMC and its peers have to deal with streaming, too. Windows for exclusive theater showings are shrinking. The pandemic has accelerated that. And if AMC gets too large and demanding for movie makers, the talent can always go to streaming faster, hurting box office sales.</p><p><blockquote>AMC 及其同行也必须处理流媒体问题。独家影院放映的窗口正在缩小。疫情加速了这一进程。如果AMC变得太大，对电影制作人的要求太高，人才总是可以更快地流向流媒体，从而损害票房销售。</blockquote></p><p> There is also the problem of the peer stocks. They aren’t trading like this is a brave new world for theaters. Cineworld stock is up 484% from its 52-week low, but shares are still off 72% from all-time highs. Cinemark shares are up 222% from their 52-week low. They are down 47% from their all-time high.</p><p><blockquote>还有同行股的问题。他们不会像这样交易，这对剧院来说是一个勇敢的新世界。Cineworld 股价较 52 周低点上涨 484%，但仍较历史高点下跌 72%。Cinemark 股价较 52 周低点上涨 222%。它们比历史高点下降了47%。</blockquote></p><p> AMC stock, again, is up almost 1,600% from its 52-week low and is down just 13% from its May all-time high.</p><p><blockquote>AMC 股价再次较 52 周低点上涨近 1,600%，较 5 月份的历史高点仅下跌 13%。</blockquote></p><p> Wall Street just doesn’t see the potential either. Nine analysts cover the stock. The average analyst price target is about $5. Before the pandemic, the average analyst price target was $15. But there were fewer shares back then. The old target enterprise value was roughly $7 billion. It’s tough to get from $7 billion to $26 billion predicting better margins.</p><p><blockquote>华尔街也看不到这种潜力。九名分析师研究了该股。分析师的平均目标价约为 5 美元。在大流行之前，分析师的平均目标价为 15 美元。但当时的股份较少。旧目标企业价值约为70亿美元。从 70 亿美元到 260 亿美元很难预测更好的利润率。</blockquote></p><p></p><p> Analysts do have positive free cash flow modeled, though–$13 million in 2022 and $90 million in 2023. That’s a long way from $600 million.</p><p><blockquote>不过，分析师确实模拟了正的自由现金流——2022 年为 1300 万美元，2023 年为 9000 万美元。这距离 6 亿美元还有很长的路要走。</blockquote></p><p> And that’s just another way of saying that AMC bulls are a long way from making the math work.</p><p><blockquote>这只是另一种说法，即 AMC 看涨者离计算成功还有很长的路要走。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/amc-rockets-higher-is-it-worth-it-maybe-51622594691?mod=hp_LEAD_1\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://www.barrons.com/articles/amc-rockets-higher-is-it-worth-it-maybe-51622594691?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188552613","content_text":"AMC Entertainment‘s skyrocketing stock price would be easy to dismiss as just meme-trade madness, that social media-fueled investor frenzy that has launched the likes of GameStop and BlackBerry into speculative territory.\nBut it’s possible that traditional investors have missed a fundamental change in the movie theater business—and it wouldn’t be the first time.\nShares of AMC (ticker: AMC) surged 23% on Tuesday, closing at $32.04—just off an all-time high of $36.72 set in late May. That puts the movie-theater chain’s market capitalization at roughly $16 billion, more than 15 times what it was in 2018, a record-breaking year at the box office. Shares were up another 34%, to $42.92, in premarket trading Wednesday.\nEven if investors missed an inflection point, though, the math doesn’t add up. The reason might be that market cap isn’t the right measure. Maybe it’s enterprise value, which is essentially market cap and debt. AMC’s enterprise value is about $26 billion, compared with $6.2 billion or so at the end of 2018.\nAMC added debt during the pandemic as theaters in the country’s biggest cities were dark for months. And the numbers make it easy to understand why: The U.S. box office in 2020 generated about $2.1 billion in ticket sales, down 81% from the 2018 record of $11.9 billion.\nSo, it seems investors have been vexed by movie theater economics. But it wouldn’t be the first time. The industry essentially went belly up at the turn of the millennium. Regal Cinemas, for instance, declared bankruptcy in 2001.\nBack then, the industry had plenty of capacity because of a new theater design—stadium seating that gave a better view of the screen. That shift meant movie theater chains had to renovate or risk losing all their patrons to movie theaters that offered the better view. In the end, too many seats and not enough patrons meant the return on the stadium-seating investments never materialized.\nThe upshot was consolidation. With fewer operators, the number of screens stabilized. Between 2002 and 2007, Regal Cinemas became a cash-generating machine because the stock was mispriced. The stock returned 21% a year on average. The S&P 500 and Dow Jones Industrial Average both returned less than 9% a year on average over the same period.\nIn those days, Regal Cinema’s enterprise value about $5 billion, or about 50% of total U.S. box office sales. That’s far short of AMC today. Something new has to be different for AMC to be worth it.\nMaybe the movie theater business is going to go through another period of consolidation, which can usher in another golden age of returns. AMC’s Tuesday gains, in fact, were catalyzed by new capital raised so the company could go on the offensive, acquiring defunct chains. Monopolies, after all, can be good for stock returns.\nIf AMC can increase market share and the U.S. box office sales can return to 2018 levels in a few years, total sales at might be $9 billion—$6 billion from tickets and $3 billion from concessions. Sales in 2018 amounted to $5.5 billion.\nThen, with better gross profit margins derived from larger scale, AMC might be able to generate $600 million in free cash flow annually, which puts the stock at about a 4% free cash flow yield. The S&P 500 trades for about a 3% free cash flow yield. The numbers can work—if they’re stretched.\nThere are problems with this scenario, though. There are lots of ifs and mights—and AMC has never generated cash flow like that in the past. Arriving at $600 million in free cash flow is more about justifying current valuations than predicting what is likely.\nAlso, with mergers and acquisitions, AMC market shares might rise, but there are still competitors. Regal Cinemas is still out there, owned by Cineworld Holdings (CINE. London). So is Cinemark (CNK). There’s not a true monopoly.\nAMC and its peers have to deal with streaming, too. Windows for exclusive theater showings are shrinking. The pandemic has accelerated that. And if AMC gets too large and demanding for movie makers, the talent can always go to streaming faster, hurting box office sales.\nThere is also the problem of the peer stocks. They aren’t trading like this is a brave new world for theaters. Cineworld stock is up 484% from its 52-week low, but shares are still off 72% from all-time highs. Cinemark shares are up 222% from their 52-week low. They are down 47% from their all-time high.\nAMC stock, again, is up almost 1,600% from its 52-week low and is down just 13% from its May all-time high.\nWall Street just doesn’t see the potential either. Nine analysts cover the stock. The average analyst price target is about $5. Before the pandemic, the average analyst price target was $15. But there were fewer shares back then. The old target enterprise value was roughly $7 billion. It’s tough to get from $7 billion to $26 billion predicting better margins.\nAnalysts do have positive free cash flow modeled, though–$13 million in 2022 and $90 million in 2023. That’s a long way from $600 million.\nAnd that’s just another way of saying that AMC bulls are a long way from making the math work.","news_type":1,"symbols_score_info":{"AMC":0.9}},"isVote":1,"tweetType":1,"viewCount":3501,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119454643,"gmtCreate":1622560637282,"gmtModify":1631889244304,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"title":"","htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/119454643","repostId":"2140617694","repostType":4,"isVote":1,"tweetType":1,"viewCount":2574,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119455704,"gmtCreate":1622560602508,"gmtModify":1631889244319,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"title":"","htmlText":"Weeee","listText":"Weeee","text":"Weeee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/119455704","repostId":"2138889344","repostType":4,"repost":{"id":"2138889344","kind":"news","pubTimestamp":1622546894,"share":"https://www.laohunote.com/m/news/2138889344?lang=zh_CN&edition=full","pubTime":"2021-06-01 19:28","market":"us","language":"en","title":"Zoom Video to Report Q1 Earnings: What's in the Cards?<blockquote>Zoom Video将公布第一季度收益：前景如何？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2138889344","media":"Zacks","summary":"Zoom Video Communications is set to report first-quarter fiscal 2022 results on Jun 1.For the quarte","content":"<p><b><a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications</b> is set to report first-quarter fiscal 2022 results on Jun 1.</p><p><blockquote><b><a href=\"https://laohu8.com/S/ZM\">缩放</a>视频通信</b>将于 6 月 1 日公布 2022 财年第一季度业绩。</blockquote></p><p>For the quarter, the company expects non-GAAP earnings between 95 cents and 97 cents per share. Total revenues are expected between $900 million and $905 million.</p><p><blockquote>该公司预计本季度非公认会计准则每股收益在 95 美分至 97 美分之间。总收入预计在 9 亿至 9.05 亿美元之间。</blockquote></p><p>The Zacks Consensus Estimate for earnings stayed at 97 cents per share over the past 30 days. The company had reported earnings of 20 cents per share in the year-ago quarter.</p><p><blockquote>过去 30 天，Zacks 对每股收益的一致预期维持在 97 美分。该公司公布去年同期每股收益为 20 美分。</blockquote></p><p>The consensus mark for revenues is pegged at $905.2 million, suggesting 175.8% growth from the figure reported in the year-ago quarter.</p><p><blockquote>收入共识为 9.052 亿美元，比去年同期增长 175.8%。</blockquote></p><p><h3>Zoom Video Communications, Inc. Price and EPS Surprise</h3><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dc75f53073be8992ce4f8cf58d4ebd0a\" tg-width=\"539\" tg-height=\"264\"><span>Zoom Video Communications, Inc. price-eps-surprise | Zoom Video Communications, Inc. Quote</span></p><p><blockquote><h3>Zoom Video通信公司。价格和每股收益惊喜</h3><p class=\"t-img-caption\"><span>Zoom Video通信公司价格-每股收益-惊喜 | Zoom Video通信公司报价</span></p></blockquote></p><p>Zoom’s earnings beat the Zacks Consensus Estimate in all of the past four quarters, the average surprise being 73.2%.</p><p><blockquote>在过去四个季度中，Zoom 的盈利都超过了 Zacks 的一致预期，平均意外率为 73.2%。</blockquote></p><p>Let’s see how things have shaped up for this announcement.</p><p><blockquote>让我们来看看这次公告的进展如何。</blockquote></p><p><h3>Factors to Watch</h3>Zoom’s fiscal first-quarter revenues are expected to have benefited from the coronavirus-induced work-from-home and online-learning wave despite the vaccination campaigns.</p><p><blockquote><h3>需要注意的因素</h3>尽管开展了疫苗接种活动，但 Zoom 第一财季的收入预计仍将受益于冠状病毒引发的在家工作和在线学习浪潮。</blockquote></p><p>Notably, the company’s freemium business model helps it win customers rapidly, whom it can later convert into paying customers. Net dollar-expansion rate on a trailing twelve-month basis was more than 156% in fourth-quarter fiscal 2021. The momentum is expected to have continued in the to-be-reported quarter.</p><p><blockquote>值得注意的是，该公司的免费增值商业模式有助于其快速赢得客户，然后将这些客户转化为付费客户。2021 财年第四季度过去 12 个月的美元净扩张率超过 156%。预计这一势头将在即将公布的季度继续下去。</blockquote></p><p>Further, the availability of Zoom For Home, which supports remote working for business professionals, has been a key catalyst.</p><p><blockquote>此外，支持商务人士远程工作的Zoom for Home的可用性一直是一个关键的催化剂。</blockquote></p><p>Additionally, this Zacks Rank #2 (Buy) company’s strong partner base, that includes the likes of <b>Atlassian</b>, <b><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a></b> and Dropbox, is expected to have benefited the company in winning enterprise customers in fiscal first quarter. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.</p><p><blockquote>此外，这家 Zacks 排名第二（买入）的公司拥有强大的合作伙伴基础，其中包括<b>阿特拉斯</b>,<b><a href=\"https://laohu8.com/S/NOW\">服务现在</a></b>和 Dropbox，预计将有助于该公司在第一财季赢得企业客户。您可以在这里查看今日 Zacks 排名第一（强力买入）股票的完整列表。</blockquote></p><p>However, Zoom Video continues to face significant competition from the likes of <b>Cisco</b>, Microsoft and Google Meet. This might have led to loss in small and medium business customers, which is likely to have hurt top-line growth.</p><p><blockquote>然而，Zoom Video继续面临来自以下公司的激烈竞争：<b>思科</b>微软和谷歌相遇。这可能会导致中小型企业客户流失，从而可能损害营收增长。</blockquote></p><p><h3>Key Q1 Highlights</h3>During the to-be-reported quarter, Zoom announced $100 million venture fund called Zoom Apps Fund, aimed at stimulating growth of Zoom’s ecosystem of Zoom Apps, integrations, developer platform and hardware.</p><p><blockquote><h3>第一季度主要亮点</h3>在即将公布的季度，Zoom 宣布成立 1 亿美元的风险投资基金，名为 Zoom Apps Fund，旨在刺激 Zoom 的 Zoom Apps、集成、开发者平台和硬件生态系统的发展。</blockquote></p><p>Moreover, during the quarter, Zoom and Formula 1 announced that they have entered a new extensive multi-year partnership across the upcoming 2021 FIA Formula One World Championship racing season and beyond.</p><p><blockquote>此外，在本季度，Zoom 和一级方程式宣布，他们已在即将到来的 2021 年国际汽联一级方程式世界锦标赛赛季及以后建立了新的广泛多年合作伙伴关系。</blockquote></p><p>Further, in February, Zoom announced the availability of Zoom Rooms that will help organizations safely re-enter the office and sustain an “everywhere workforce”.</p><p><blockquote>此外，Zoom 在 2 月份宣布推出 Zoom Rooms，这将帮助组织安全地重新进入办公室，并维持 “无处不在的员工队伍”。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zoom Video to Report Q1 Earnings: What's in the Cards?<blockquote>Zoom Video将公布第一季度收益：前景如何？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZoom Video to Report Q1 Earnings: What's in the Cards?<blockquote>Zoom Video将公布第一季度收益：前景如何？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Zacks</strong><span class=\"h-time small\">2021-06-01 19:28</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b><a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications</b> is set to report first-quarter fiscal 2022 results on Jun 1.</p><p><blockquote><b><a href=\"https://laohu8.com/S/ZM\">缩放</a>视频通信</b>将于 6 月 1 日公布 2022 财年第一季度业绩。</blockquote></p><p>For the quarter, the company expects non-GAAP earnings between 95 cents and 97 cents per share. Total revenues are expected between $900 million and $905 million.</p><p><blockquote>该公司预计本季度非公认会计准则每股收益在 95 美分至 97 美分之间。总收入预计在 9 亿至 9.05 亿美元之间。</blockquote></p><p>The Zacks Consensus Estimate for earnings stayed at 97 cents per share over the past 30 days. The company had reported earnings of 20 cents per share in the year-ago quarter.</p><p><blockquote>过去 30 天，Zacks 对每股收益的一致预期维持在 97 美分。该公司公布去年同期每股收益为 20 美分。</blockquote></p><p>The consensus mark for revenues is pegged at $905.2 million, suggesting 175.8% growth from the figure reported in the year-ago quarter.</p><p><blockquote>收入共识为 9.052 亿美元，比去年同期增长 175.8%。</blockquote></p><p><h3>Zoom Video Communications, Inc. Price and EPS Surprise</h3><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dc75f53073be8992ce4f8cf58d4ebd0a\" tg-width=\"539\" tg-height=\"264\"><span>Zoom Video Communications, Inc. price-eps-surprise | Zoom Video Communications, Inc. Quote</span></p><p><blockquote><h3>Zoom Video通信公司。价格和每股收益惊喜</h3><p class=\"t-img-caption\"><span>Zoom Video通信公司价格-每股收益-惊喜 | Zoom Video通信公司报价</span></p></blockquote></p><p>Zoom’s earnings beat the Zacks Consensus Estimate in all of the past four quarters, the average surprise being 73.2%.</p><p><blockquote>在过去四个季度中，Zoom 的盈利都超过了 Zacks 的一致预期，平均意外率为 73.2%。</blockquote></p><p>Let’s see how things have shaped up for this announcement.</p><p><blockquote>让我们来看看这次公告的进展如何。</blockquote></p><p><h3>Factors to Watch</h3>Zoom’s fiscal first-quarter revenues are expected to have benefited from the coronavirus-induced work-from-home and online-learning wave despite the vaccination campaigns.</p><p><blockquote><h3>需要注意的因素</h3>尽管开展了疫苗接种活动，但 Zoom 第一财季的收入预计仍将受益于冠状病毒引发的在家工作和在线学习浪潮。</blockquote></p><p>Notably, the company’s freemium business model helps it win customers rapidly, whom it can later convert into paying customers. Net dollar-expansion rate on a trailing twelve-month basis was more than 156% in fourth-quarter fiscal 2021. The momentum is expected to have continued in the to-be-reported quarter.</p><p><blockquote>值得注意的是，该公司的免费增值商业模式有助于其快速赢得客户，然后将这些客户转化为付费客户。2021 财年第四季度过去 12 个月的美元净扩张率超过 156%。预计这一势头将在即将公布的季度继续下去。</blockquote></p><p>Further, the availability of Zoom For Home, which supports remote working for business professionals, has been a key catalyst.</p><p><blockquote>此外，支持商务人士远程工作的Zoom for Home的可用性一直是一个关键的催化剂。</blockquote></p><p>Additionally, this Zacks Rank #2 (Buy) company’s strong partner base, that includes the likes of <b>Atlassian</b>, <b><a href=\"https://laohu8.com/S/NOW\">ServiceNow</a></b> and Dropbox, is expected to have benefited the company in winning enterprise customers in fiscal first quarter. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.</p><p><blockquote>此外，这家 Zacks 排名第二（买入）的公司拥有强大的合作伙伴基础，其中包括<b>阿特拉斯</b>,<b><a href=\"https://laohu8.com/S/NOW\">服务现在</a></b>和 Dropbox，预计将有助于该公司在第一财季赢得企业客户。您可以在这里查看今日 Zacks 排名第一（强力买入）股票的完整列表。</blockquote></p><p>However, Zoom Video continues to face significant competition from the likes of <b>Cisco</b>, Microsoft and Google Meet. This might have led to loss in small and medium business customers, which is likely to have hurt top-line growth.</p><p><blockquote>然而，Zoom Video继续面临来自以下公司的激烈竞争：<b>思科</b>微软和谷歌相遇。这可能会导致中小型企业客户流失，从而可能损害营收增长。</blockquote></p><p><h3>Key Q1 Highlights</h3>During the to-be-reported quarter, Zoom announced $100 million venture fund called Zoom Apps Fund, aimed at stimulating growth of Zoom’s ecosystem of Zoom Apps, integrations, developer platform and hardware.</p><p><blockquote><h3>第一季度主要亮点</h3>在即将公布的季度，Zoom 宣布成立 1 亿美元的风险投资基金，名为 Zoom Apps Fund，旨在刺激 Zoom 的 Zoom Apps、集成、开发者平台和硬件生态系统的发展。</blockquote></p><p>Moreover, during the quarter, Zoom and Formula 1 announced that they have entered a new extensive multi-year partnership across the upcoming 2021 FIA Formula One World Championship racing season and beyond.</p><p><blockquote>此外，在本季度，Zoom 和一级方程式宣布，他们已在即将到来的 2021 年国际汽联一级方程式世界锦标赛赛季及以后建立了新的广泛多年合作伙伴关系。</blockquote></p><p>Further, in February, Zoom announced the availability of Zoom Rooms that will help organizations safely re-enter the office and sustain an “everywhere workforce”.</p><p><blockquote>此外，Zoom 在 2 月份宣布推出 Zoom Rooms，这将帮助组织安全地重新进入办公室，并维持 “无处不在的员工队伍”。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.zacks.com/stock/news/1619568/zoom-video-zm-to-report-q1-earnings-whats-in-the-cards?art_rec=quote-stock_overview-zacks_news-ID05-txt-1619568\">Zacks</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZM":"Zoom"},"source_url":"https://www.zacks.com/stock/news/1619568/zoom-video-zm-to-report-q1-earnings-whats-in-the-cards?art_rec=quote-stock_overview-zacks_news-ID05-txt-1619568","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138889344","content_text":"Zoom Video Communications is set to report first-quarter fiscal 2022 results on Jun 1.For the quarter, the company expects non-GAAP earnings between 95 cents and 97 cents per share. Total revenues are expected between $900 million and $905 million.The Zacks Consensus Estimate for earnings stayed at 97 cents per share over the past 30 days. The company had reported earnings of 20 cents per share in the year-ago quarter.The consensus mark for revenues is pegged at $905.2 million, suggesting 175.8% growth from the figure reported in the year-ago quarter.Zoom Video Communications, Inc. Price and EPS SurpriseZoom Video Communications, Inc. price-eps-surprise | Zoom Video Communications, Inc. QuoteZoom’s earnings beat the Zacks Consensus Estimate in all of the past four quarters, the average surprise being 73.2%.Let’s see how things have shaped up for this announcement.Factors to WatchZoom’s fiscal first-quarter revenues are expected to have benefited from the coronavirus-induced work-from-home and online-learning wave despite the vaccination campaigns.Notably, the company’s freemium business model helps it win customers rapidly, whom it can later convert into paying customers. Net dollar-expansion rate on a trailing twelve-month basis was more than 156% in fourth-quarter fiscal 2021. The momentum is expected to have continued in the to-be-reported quarter.Further, the availability of Zoom For Home, which supports remote working for business professionals, has been a key catalyst.Additionally, this Zacks Rank #2 (Buy) company’s strong partner base, that includes the likes of Atlassian, ServiceNow and Dropbox, is expected to have benefited the company in winning enterprise customers in fiscal first quarter. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.However, Zoom Video continues to face significant competition from the likes of Cisco, Microsoft and Google Meet. This might have led to loss in small and medium business customers, which is likely to have hurt top-line growth.Key Q1 HighlightsDuring the to-be-reported quarter, Zoom announced $100 million venture fund called Zoom Apps Fund, aimed at stimulating growth of Zoom’s ecosystem of Zoom Apps, integrations, developer platform and hardware.Moreover, during the quarter, Zoom and Formula 1 announced that they have entered a new extensive multi-year partnership across the upcoming 2021 FIA Formula One World Championship racing season and beyond.Further, in February, Zoom announced the availability of Zoom Rooms that will help organizations safely re-enter the office and sustain an “everywhere workforce”.","news_type":1,"symbols_score_info":{"ZM":0.9}},"isVote":1,"tweetType":1,"viewCount":3586,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":134326282,"gmtCreate":1622209102946,"gmtModify":1631889244334,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"title":"","htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/134326282","repostId":"2138107027","repostType":4,"isVote":1,"tweetType":1,"viewCount":4080,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":135084783,"gmtCreate":1622122701142,"gmtModify":1631889244340,"author":{"id":"3579418112520180","authorId":"3579418112520180","name":"LIHUI","avatar":"https://static.tigerbbs.com/74e419c79093348e7ec1d10e5b39e08e","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579418112520180","idStr":"3579418112520180"},"themes":[],"title":"","htmlText":".guu ya n","listText":".guu ya n","text":".guu ya n","images":[{"img":"https://static.tigerbbs.com/f718b1732852edbe5f41671c8998e94e","width":"1125","height":"3282"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/135084783","isVote":1,"tweetType":1,"viewCount":3454,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}